Axium Neurostimulator System
ABBOTT MEDICAL · Decision date Feb 11, 2016
What did the FDA approve?
FDA approved the Axium Spinal Modulation Neurostimulator System on February 11, 2016, under PMA number P150004. The approval covers spinal column stimulation through epidural and intra-spinal lead access to the dorsal root ganglion as an aid in managing moderate to severe chronic intractable pain of the lower limbs in adults with Complex Regional Pain Syndrome types I and II.
The statement notes that ACCURATE study subjects had failed at least two prior pharmacologic treatments from at least two drug classes and continued pharmacologic therapy during the study. It also records the 1994 IASP consensus renaming of reflex sympathetic dystrophy and causalgia as CRPS types I and II, respectively. The source does not report independent safety or effectiveness findings beyond the approval decision.
FDA approval order statement
Approval for the Axium Spinal Modulation Neurostimulator System. This device is indicated for: spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable* pain of the lower limbs in adult patients with Complex Regional Pain Syndrome (CRPS) types I and II**. * Study subjects from the ACCURATE clinical study had failed to achieve adequate pain relief from at least 2 prior pharmacologic treatments from at least 2 different drug classes and continued their pharmacologic therapy during the clinical study. ** Please note that in 1994, a consensus group of pain medicine experts gathered by the International Association for the Study of Pain (IASP) reviewed diagnostic criteria and agreed to rename reflex sympathetic dystrophy (RSD) and causalgia, as complex regional pain syndrome (CRPS) types I and II, respectively.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Feb 11, 2016
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150004
- Regulatory pathway
- Premarket approval application
- Applicant
- ABBOTT MEDICAL
- Product code
- PMP
- Decision code
- APPR
- Decision date
- Feb 11, 2016
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Dorsal root ganglion stimulator for pain relief.
- Applicant
- Abbott Medical
- Product code
- PMP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P150004 received
Application receipt date recorded by FDA.
P150004 · FDA decision
APPR
P150004/S100 · Related supplement
Proclaim DRG IPG
P150004/S101 · Related supplement
Dorsal Root Ganglion Stimulation (DRG) EPG
Timeline entries are records held by MedtechLedger for P150004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Proclaim DRG IPGP150004/S100 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
Dorsal Root Ganglion Stimulation (DRG) EPGP150004/S101 | ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P150004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
